RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RVU-120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RVU-120 is under development for the treatment of hematological tumors, acute lymphoblastic leukemia, triple negative breast cancer, myeloproliferative disorders, lymphomas including mantle cell lymphoma, non-Hodgkin lymphoma, solid tumors including colorectal cancer, breast cancer, prostate cancer, Wilms tumor and rare anemia including Diamond Blackfan anemia (congenital hypoplastic anemia), relapsed/refractory acute myeloid leukemia, diffuse large B-cell lymphoma and myelodysplastic syndrome. The drug candidate is administered through oral route. It acts by targeting Cyclin Dependent Kinase 19 and Cyclin Dependent Kinase 8.
Ryvu Therapeutics overview
Ryvu Therapeutics is a biopharmaceutical company that specializes in novel small molecule therapies addressing high-value emerging targets in precision oncology. Ryvu Therapeutics is headquartered in Krakow, Poland.
For a complete picture of RVU-120’s drug-specific PTSR and LoA scores, buy the report here.